Biotechnology: 1Q26 Earnings Roundup: ABSI, ALEC, CGEM, CGON, CTNM, DNLI, EIKN, ERAS, GENB, IRON, RXRX, SDGR

Research evidence excerpt

Biotechnology: 1Q26 Earnings Roundup: ABSI, ALEC, CGEM, CGON, CTNM, DNLI, EIKN, ERAS, GENB, IRON, RXRX, SDGR

Idea

May 14, 2026 03:50 AM GMT

Morgan Stanley & Co. LLCMBiotechnology | North America Sean Laaman, Ph.D.

Equity Analyst

1Q26 Earnings Roundup: ABSI, Sean.Laaman@morganstanley.comMorgan K Gryga +1 212 761-4947

Research Associate

Morgan.Gryga@morganstanley.com +1 212 761-0824

ALEC, CGEM, CGON, CTNM, Katherine Sun

Katherine.Sun@morganstanley.com +1 212 761-5968

DNLI, EIKN, ERAS, GENB, IRON, Michael H Riad, Ph.D.

Michael.Riad@morganstanley.com +1 212 761-1309

RXRX, SDGR

Biotechnology

North America

What’s Changed Industry View Attractive

ABSCI CORP (ABSI.O) From To

Price Target $4.20 $4.10

Contineum Therapeutics (CTNM.O)

Price Target $14.00 $16.00

Denali Therapeutics Inc (DNLI.O)

Price Target $42.00 $40.00

Disc Medicine Inc (IRON.O)

Price Target $75.00 $80.00

Generate Biomedicines Inc (GENB.O)

Price Target $20.00 $22.00

Recursion Pharmaceuticals Inc (RXRX.O)

Price Target $5.00 $5.50

Schrodinger Inc. (SDGR.O)

Price Target $19.00 $17.00

We include key takeaways following 1Q26 earnings updates

across the following covered companies: ABSI, ALEC, CGEM,

CGON, CTNM, DNLI, EIKN, ERAS, GENB, IRON, RXRX, SDGR.

Absci (ABSI, EW, $4.10 PT): Absci reported continued clinical progress for lead

asset ABS‑201, with the Phase 1/2a HEADLINE trial advancing on plan as all SAD

cohorts have completed dosing and the first MAD cohort in AGA has been initiated;

to date, the program remains well tolerated with favorable emerging safety data,

and preliminary PK supports a differentiated, infrequent dosing paradigm of ~2–3

injections over six months (with potential for ≥Q8W dosing), reinforcing

management’s view of a durable, convenient profile. The company expects to share